## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

#### FORM 8-K

## CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 4, 2016

SECOND SIGHT MEDICAL PRODUCTS, INC.			
	(Exact Name of Registrant as Specified in Its Charter)		
	California		
	(State or Other Jurisdiction of Incorporation)		
	333-198073 02-0692322		
	(Commission File Number) (IRS Employer Identification No.)		
	12744 Car Farmanda Band Code 400		
12744 San Fernando Road, Suite 400 Sylmar, California 91342			
(Address of Principal Executive Offices)			
(818) 833-5000			
(Registrant's Telephone Number, Including Area Code)			
(Former Name or Former Address, if Changed Since Last Report)			
	Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following General Instruction A.2. below):	g provisions (see	
	☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)		
	□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
	□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
	□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		

### ITEM 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective January 4, 2016, Anne-Marie Ripley resigned as Vice President, Regulatory & Clinical Affairs of Second Sight Medical Products, Inc. (the "Company"). Ms. Ripley will continue to provide consulting services to the Company under a 12 month consulting agreement pursuant to which Ms. Ripley has agreed to provide us with her consulting services on an as needed basis through December 31, 2016.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 6, 2016

# SECOND SIGHT MEDICAL PRODUCTS, INC.

/s/ Thomas B. Miller By: Thomas B. Miller Chief Financial Officer